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Key Points
• A randomized placebo-
controlled trial of the
cysteinyl leukotriene in-
hibitor montelukast did
not demonstrate an im-
provement in pain.
Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle
cell disease (SCD), levels of CysLTs are increased comparedwith controls and associatedwith
a higher rate of hospitalization for pain. We tested the hypothesis that administration of the
CysLT receptor antagonistmontelukast would improve SCD-related comorbidities, including
pain, in adolescents and adults with SCD. In a phase 2 randomized trial, we administered
montelukast or placebo for 8 weeks. The primary outcome measure was a .30% reduction
in soluble vascular cell adhesion molecule 1 (sVCAM), a marker of vascular injury.
Secondary outcome measures were reduction in daily pain, improvement in pulmonary
function, and improvement in microvascular blood flow, as measured by laser Doppler
velocimetry. Forty-two participants with SCD were randomized to receive montelukast or
placebo for 8 weeks. We found no difference between the montelukast and placebo groups
with regard to the levels of sVCAM, reported pain, pulmonary function, or microvascular
blood flow. Although montelukast is an effective treatment for asthma, we did not find
benefit for SCD-related outcomes. This clinical trial was registered at www.clinicaltrials.gov
as #NCT01960413.
Introduction
Inflammation is critical to sickle cell disease (SCD) pathogenesis. Inflammatory mediators attract and
activate white blood cells, promote vascular adhesion and coagulation, and sensitize neurons in the
peripheral and central nervous system; all of these processes can worsen acute and chronic SCD pain.1
Reduction of inflammation, including with therapies traditionally used to treat allergic inflammation, is
a proven strategy to treat or prevent SCD pain.2,3
Leukotrienes (LTs), a unique family of lipids known for their role in promoting inflammation in asthma and
other allergic disorders, are a potential therapeutic target for patients with SCD.4,5 The LT pathway
begins with the enzymatic actions of 5-lipoxygenase on arachidonic acid, which leads to the generation
of leukotriene A4 (LTA4), a common LT precursor. LTA4 is then converted to LTB4 or cysteinyl
leukotrienes (CysLTs; LTC4, LTD4, and LTE4). LTB4 is primarily a leukocyte chemoattractor and
activator.5 CysLTs act in the airway to promote bronchoconstriction, airway remodeling, mucus
production, and smooth muscle proliferation,6-8 actions that are the basis for CysLT’s role in asthma.
Clinically, levels of CysLTs correlate with asthma severity,9 asthma exacerbations,10 allergen
challenge,11,12 and exercise-induced bronchoconstriction.13 In addition to the airways, CysLTs have
actions elsewhere. In the vasculature, CysLTs mediate vasoconstriction14 and upregulation of cell
adhesion molecules15 and increase vascular permeability.6 In the nervous system, CysLTs interact with
the dorsal root ganglion to promote the development of neuropathic pain.16 Multiple cell types produce
CysLTs. In the periphery, CysLTs are produced primarily by leukocytes, including mast cells,
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macrophages, basophils, and eosinophils. In the central nervous
system, CysLTs can be produced by and bind to microglial cells,
which are resident mononuclear phagocytes that are important to
neuronal plasticity.17 Previously, our group examined levels of
CysLTs in patients with SCD and found that they are increased
compared with healthy controls, and higher levels correlate with
increased rates of hospitalization for pain.18,19 Notably, these levels
were not associated with asthma diagnosis. During an acute pain
episode, levels of CysLTs increased further.20
Based on these data and the known actions of CysLTs, including
suggestions of the involvement of CysLTs in neuropathic pain,17,21
we sought to test the hypothesis that blocking CysLTs would
reduce SCD-related comorbidities, including pain. In a phase 2
study, we randomized adolescents and adults with SCD, but
without asthma, to an 8-week course of montelukast or placebo. All
participants were required to be on stable-dose hydroxyurea,
because it is a well-established therapy for SCD pain. Our primary
outcome measure was a marker of vascular injury, soluble vascular
cell adhesion molecule 1 (sVCAM). Secondary measures included
daily pain, pulmonary function, and microvascular blood flow, as
measured by laser Doppler velocimetry (LDV).
Methods
Study conduct
This was a double-blind placebo-controlled phase 2 trial conducted
at Vanderbilt University and the Medical College of Wisconsin/
Froedtert Hospital. This clinical trial was registered at www.
clinicaltrials.gov as #NCT01960413 (IND number 76997). The
study was approved by the Institutional Review Boards at Vanderbilt
University and the Medical College ofWisconsin. Study participants
were block randomized ($25 or,25 years) to receive montelukast
or placebo for 8 weeks. Key eligibility criteria were HbSS/HbSb0
thalassemia, age 16 to 60 years, on a stable dose of hydroxyurea for
$2 months, $2 episodes of pain in the last 12 months, and no
diagnosis of asthma.
Drug formulation
Montelukast, 10 mg, was ground and combined with microcrystal-
line cellulose to pack a size #1 pink opaque capsule, so that each
capsule contained 10 mg of montelukast. Placebo capsules were
also size #1 opaque pink and contained only microcrystalline
cellulose.
Biomarkers
Blood samples for inflammatory markers were collected preran-
domization, at randomization, and at weeks 4 and 8. Whole-blood
samples were collected in a 5-mL light blue top citrate tube and
centrifuged at 1500g for 15 minutes. Plasma was aliquoted into 4
Eppendorf tubes and immediately frozen at 280°C. Clean-catch
urine samples were collected by standard methods. Urine was
processed within 2 hours of collection by centrifugation (1500g,
15 minutes) to remove particulates. Urine specimens were
aliquoted and frozen at 280°C. Samples were stored frozen at
280°C until shipped or analyzed. Samples from Nashville were
batched and shipped on dry ice overnight by FedEx to the
laboratory of J.J.F. in Milwaukee, Wisconsin. Cytokines interleukin-
1b, interleukin-6, tumor necrosis factor-a, and interferon-g were
measured with a high-sensitivity human-specific multiplex cytokine
assay kit (Life Technologies). To determine plasma levels of
human-specific sVCAM, soluble E-selectin (sE-sel), and soluble
P-selectin (sP-sel), enzyme-linked immunosorbent assay kits
DVC00, DSLE00, and BBE6 were used, respectively (R&D
Systems/Bio-Techne). Urine levels of LTE4 were measured by
enzyme-linked immunosorbent assay and normalized to urine
creatinine levels determined by colorimetric assay (both from
Cayman Chemical).
Diary
Study participants completed a daily diary in which they were asked
to rate their maximum daily pain score on a scale from 0 to 9 (0 is no
pain and 9 is greatest pain) and whether they were having a “crisis.”
The diary was initiated in a 14-day lead-in period to establish
a baseline, and it was continued through the study.
Pulmonary function test
Spirometry, diffusion capacity of carbon monoxide, and lung
volumes were tested according to American Thoracic Society
criteria.22,23 We obtained pre- and postbronchodilator measure-
ments (albuterol, 4 puffs from a metered dose inhaler administered
by an aerochamber), using a calibrated spirometer. While seated,
the participants were encouraged to perform between 5 and 8
maneuvers to obtain 3 acceptable tracings. Up to 5 maneuvers
were repeated after inhalation of an albuterol inhaler. The adequacy
of the blows was judged using Epidemiologic Standardization
Criteria: a minimum duration of 6 seconds, back extrapolated
volume ,5%, forced vital capacity (FVC) within 5% or 200 cc, and
assessment by the technician of the adequacy of the effort. For lung
volumes, patients were tested with body plethysmography. To
ensure American Thoracic Society criteria were met across the 2
participating sites for spirometry, test results were overseen a single
pulmonologist.
LDV
We measured changes in blood flow with LDV (PeriFlux System
5000) assessment of the microcirculation in the patient’s forearm
using standard methodology prerandomization and again at week
8.24 LDV is a noninvasive methodology that can be performed at the
bedside. Two probes were adhered to the participant’s forearm,
each at a position not overlying a visible large blue vein or a palpable
vein and where the baseline flow is ,20 PU, and a blood pressure
cuff is placed on the upper arm. To characterize the hyperemic
blood flow after temporary occlusion of flow (postocclusion reactive
hyperemia), once a stable LDV tracing was obtained for 30
seconds, the cuff was inflated to 200 mmHg for 3 minutes and then
the pressure was released. Readings were recorded after release of
occlusion to capture a postocclusive peak in the LDV tracing and
after the flow becomes stable (;2-4 minutes). The LDV tests were
performed at the Medical College of Wisconsin.
Statistical analysis
Data analysis. Continuous variables are reported as median,
range, or interquartile range (IQR), and categorical variables are
reported as frequencies (%). To examine the differences between
the control and montelukast groups, the Fisher’s exact test was
used for categorical variables, and the Mann-Whitney U test was
used for continuous variables. For the primary outcome (plasma
levels of sVCAM), a mixed model intent-to-treat analysis was
performed to examine for trends or group differences over time.
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Logarithm base 10 was applied to the primary outcome to satisfy
parametric assumptions about the link function. Intercept and slope
(measured in weeks) were included as the random terms to
estimate the deviation of each participant from the overall group, the
covariance structure used was unstructured, and parameters were
estimated using maximum likelihood method.
Power analysis. We planned to accrue 25 participants in each
arm. From preliminary data, the mean sVCAM level is 353 ng/mL,
with a standard deviation of 104 ng/mL. If we had similar variability in
the proposed study, we would have been able to detect a change
$62 ng/mL (or 18%) with 80% power. A 2-sided P , .05 was
considered significant. All analyses were conducted using SAS
9.4 or SPSS Version 24.
Results
A total of 78 patients signed consent and was screened
(supplemental Figure). Of these, 19 participants failed screening
and 13 withdrew before randomization, resulting in a total of 46
eligible participants who were randomized. After the randomization,
5 participants did not continue: 2 subjects were lost to follow-up, 2
participants withdrew themselves from the study, and 1 subject was
withdrawn by the principal investigator. Only 1 of these subjects
had a postrandomization measure of the primary outcome, sVCAM.
A total of 41 participants completed the study (Table 1). Of those,
20 received montelukast, and 21 received placebo. Seventeen
participants were male, and median age was 26.5 years. There were
no differences in age, sex, laboratory values, or number of painful
episodes requiring hospital admission in the 3 years prior to study
between the montelukast and control groups.
Plasma markers of vaso-occlusive crisis–associated
tissue injury
The mixed-model analysis, used for an intent-to-treat analysis (46
total patients, 42 of whom had an end-of-study sVCAM measure-
ment), found that there was no significant group difference or trend
over time. The change in plasma levels in sVCAM before and after
montelukast vs placebo was not significantly different between the
groups (P 5 .16; Table 2). There also was no difference in plasma
sP-sel levels (P 5 .98) or sE-sel levels (P 5 .88) between the
montelukast and placebo groups before and after 8 weeks of
treatment (Table 2).
Urine measurements
Levels of urine LTE4 were not significantly different between the
montelukast and placebo groups before and after 8 weeks of
treatment (P 5 .74; Table 2).
Pain outcomes
Prior to randomization, when participants maintained a 14-day pain
diary, there were fewer reported pain crisis episodes in the
montelukast group compared with the placebo group. There was
no change in any of the pain outcomes after 8 weeks of treatment
compared with before treatment in the montelukast and placebo
groups (Table 2). We also examined the montelukast-treated group
by itself to determine whether any of the biomarkers pretreatment
would predict pain response to montelukast but did not find any
association between pre-LTE4, sVCAM, p-selectin, substance P
levels, or white blood cell count and improvement in any pain
parameter (percentage change in mean or median pain score or
percentage of days with pain score . 5; data not shown).
Pulmonary function
There was a difference in FVC between the montelukast and
placebo groups prerandomization (P 5 .024). There was no
significant group difference in the percentage of change in forced
expiratory volume in 1 second, FVC, or forced expiratory volume in 1
second/FVC (Table 2).
LDV
Twenty-one participants in Milwaukee completed the LDV test: 10
in the placebo group and 11 in the montelukast group. There was
no significant increase in microvascular blood flow in any measured
parameter using LDV in the group receiving montelukast vs placebo
(P5 .07). The group comparisons of time to half-peak of hyperemia
are shown in Table 2.
Discussion
Montelukast is a CysLT receptor 1 inhibitor that is widely used for
the treatment of asthma. Members of our investigative group have
demonstrated that a diagnosis of asthma is associated with an
increased rate of pain, acute chest syndrome, and mortality in
children with SCD.25,26 It would not be surprising if montelukast
improved asthma symptoms in patients with SCD. However, in this
study, we sought to determine whether montelukast would improve
Table 1. Patient demographics
Placebo (n 5 21) Montelukast (n 5 20) P
Male, n (%) 8 (38) 9 (45) .76
Age, median (range), y 27 (19-52) 26.5 (16-64) .96
Hospitalizations in last 3 y, n 2 (0-3) 3 (1.5-7) .13
ED visits in last 3 y, n 2 (1-4) 5 (1.5-7) .16
Admissions for pain crises in last 3 y, n 7.5 (4-15) 10 (6.5-20) .46
WBC, 3109/L 7.1 (5.5-8.6) 7.6 (5.5-9.4) .50
Hb, g/dL 8.7 (8.2-9.7) 9.1 (8.3-9.9) .34
Reticulocyte count (%), % 8.85 (5.50-13.1) 9.15 (8.35-9.9) .53
Hb, hemoglobin; WBC, white blood cell count.
Unless otherwise noted, data are median (IQR).
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Table 2. Outcome measures in patients treated with placebo and montelukast
Placebo (n 5 20) Montelukast (n 5 20) P
sVCAM, ng/mL
Prerandomization 945.0 (814.0-1254.5) 956.0 (694.0-1080.0) .44
Week 8 900.5 (865.5-1403.5) 908.5 (668.0-1158.5) .37
% Change 4.17 (23.3 to 112.1) 23.2 (213.6 to 111.6) .16
sP-sel, ng/mL
Prerandomization 44.5 (35.0-63.5) 49.5 (43.0-62.5) .24
Week 8 46.5 (31.0-52.5) 49.5 (35.5-59.5) .18
% Change 26.2 (221.1 to 114.7) 27.7 (221.4 to 111.2) .98
sE-sel, ng/mL
Prerandomization 45.0 (31.5-61.0) 52.5 (33.0-65.5) .47
Week 8 44.0 (30.5-55.0) 49.5 (34.0-55.0) .53
% Change 27.4 (214.8 to 0) 22.5 (218.5 to 18.9) .88
LTE4, pg/mg
Prerandomization 2145.5 (1607.0-2643.0) 2055.5 (1579.0-2493.5) .66
Week 8 1920.5 (1666.0-2339.0) 1787.5 (1480.5-2196.5) .39
% Change 23.1 (221.3 to 133.0) 210.0 (229.7 to 128.6) .74
Daily mean pain score
Prerandomization 5.0 (3.8-5.9) 4.3 (4.0-5.0) .20
Postrandomization 5.2 (3.9-5.8) 4.6 (3.2-6.3) .29
% Change 23.8 (212.9 to 115.4) 5.7 (27.7 to 131.8) .42
Daily median pain score
Prerandomization 5.0 (4.0-6.0) 4.0 (4.0-5.0) .29
Postrandomization 5.0 (4.0-6.0) 4.0 (3.0-5.5) .20
% Change 0 (216.7 to 115.5) 0 (0-33.3) .53
Pain days with pain score ‡5, %
Prerandomization 15.5 (6.7-42.9) 13.4 (0-23.8) .31
Postrandomization 14.9 (3.5-31.5) 4 (1.8-13.2) .09
% Change 21.5 (24.7 to 11.4) 22.5 (212.5 to 12.6) .78
Days with pain crisis episode, %
Prerandomization 4.6 (0-16.7) 0 (0-0) .024
Postrandomization 3.5 (0-15.8) 0 (0-2.5) .030
% Change 0 (24.6 to 13.5) 0 (0-1.5) .58
FEV1 predicted, %
Prerandomization 83.0 (74.0-91.0) 92.0 (81.0-100.5) .06
Week 8 82.0 (70.0-94.0) 86.5 (77.0-100.0) .22
% Change 21.2 (24.1 to 14.1) 22.2 (28.6 to 11.64) .84
FVC predicted, %
Prerandomization 82.0 (80.0-95.0) 96 (87.5-106.0) .024
Week 8 84 (75-99) 92.5 (85.5-103.5) .09
% Change 1.0 (21.9 to 14.0) 21.5 (24.3 to 13.8) .35
FEV1/FVC predicted, %
Prerandomization 83.0 (78.0-98.0) 86.0 (80.0-93.5) .73
Week 8 84.0 (75.0-98.0) 85.0 (78.0-96.5) .0
% Change 0 (23.9 to 11.4) 1.8 (21.7 to 12.9) .27
TLC predicted, %
Prerandomization 88.0 (79.0-92.0) 99.0 (88.0-114.0) .044
Week 8 88.0 (79.0-97.0) 94.0 (87.0-109.0) .17
Twenty-one patients underwent LDV (10 placebo and 11 montelukast). TLC predicted values were available for 20 patients (9 placebo and 11 montelukast). Data are median (IQR).
FEV1, forced expiratory volume in 1 second; TH1, time to half-peak of hyperemia.
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SCD comorbidities, such as inflammation and pain, independent of its
effects in the lung. We found that, in subjects treated with montelukast
vs placebo, there was no difference in markers of vascular inflammation,
pain, pulmonary function, or microvascular blood flow.
LTs are a unique family of lipids known for their roles in promoting
inflammation.5 The production of LTs begins when 5-lipoxygenase
converts arachidonic acid to LTA4, which is subsequently converted
to LTB4 or CysLTs (LTC4, LTD4, and LTE4). LTB4 and CysLTs have
been reported to be elevated in SCD patients compared with
healthy controls, and levels of CysLTs increase further during acute
pain episodes.18-20,27 One mechanism for increased LT production
in SCD involves increased secretion of placenta growth factor by
erythroid cells.28 Placenta growth factor released into the
circulation targets mononuclear cells, including mast cells, causing
hypoxia-independent activation of HIF-1a and stimulating LT
production and cytochemokine expression.28
There is evidence that LTs can promote pain. In animal models,
CysLTs and CysLT receptors are expressed by microglial cells in
the spinal cord; their activation could, in turn, activate dorsal root
ganglions.29 Studies in rat models of spinal cord injury and chronic
constriction injury demonstrated that blocking CysLT receptor 1
with montelukast or pranlukast decreased the threshold at which
mechanical and thermal withdrawal occurred during quantitative
sensory testing.30 Another study confirmed these results, demon-
strating that montelukast could prevent the development of
neuropathic pain after ischemia-reperfusion injury in rats.31 In 1 of
the few clinical studies to date, children treated with montelukast for
the management of postoperative tonsillectomy pain required
a smaller amount of rescue analgesics.32 In another study, montelukast
had an antinociceptive effect in children and adolescents with
dyspepsia and duodenal eosinophilia.33
The reason why montelukast did not affect pain in our study is
not clear. Potentially, the increased levels of CysLTs that we
demonstrated previously are a marker of acute pain events but are
not involved in their pathogenesis. Acute and chronic pain in SCD
has a unique and complex pathogenesis; the role of CysLTs that
has been established in animal models and patients without SCD
may not be the same in SCD. Other possibilities are (1) the
confounding effects of nonsteroidal anti-inflammatory drugs or
aspirin on pain or biomarkers, (2) montelukast does not result in
therapeutic levels in the central nervous system, and (3) our sample
size was not large enough to detect differences in pain, especially
because our study was not powered to detect differences in pain.
The lower percentage of days with pain crises in the montelukast
group also could have affected our ability to find an effect of the
drug. Finally, it is also possible that the biology accounting for the
chronic nature of SCD pain may not be reversible with montelukast.
Although this study did not have positive findings, it was an
important one to conduct given the preliminary evidence that
demonstrated an association between elevated levels of CysLTs
and acute SCD pain. Montelukast might still have an important role
in the management of asthma in patients with SCD, and the findings
of this study should not dissuade providers from using it in that
setting.
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